Pirfenidone inhibits myofibroblast differentiation and lung fibrosis development during insufficient mitophagy

BACKGROUND: Pirfenidone (PFD) is an anti-fibrotic agent used to treat idiopathic pulmonary fibrosis (IPF), but its precise mechanism of action remains elusive. Accumulation of profibrotic myofibroblasts is a crucial process for fibrotic remodeling in IPF. Recent findings show participation of autoph...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Respir Res
Main Authors: Kurita, Yusuke, Araya, Jun, Minagawa, Shunsuke, Hara, Hiromichi, Ichikawa, Akihiro, Saito, Nayuta, Kadota, Tsukasa, Tsubouchi, Kazuya, Sato, Nahoko, Yoshida, Masahiro, Kobayashi, Kenji, Ito, Saburo, Fujita, Yu, Utsumi, Hirofumi, Yanagisawa, Haruhiko, Hashimoto, Mitsuo, Wakui, Hiroshi, Yoshii, Yutaka, Ishikawa, Takeo, Numata, Takanori, Kaneko, Yumi, Asano, Hisatoshi, Yamashita, Makoto, Odaka, Makoto, Morikawa, Toshiaki, Nakayama, Katsutoshi, Kuwano, Kazuyoshi
פורמט: Artigo
שפה:Inglês
יצא לאור: BioMed Central 2017
נושאים:
Research
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5457546/
https://ncbi.nlm.nih.gov/pubmed/28577568
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-017-0600-3
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים